AstraZeneca Completes Acquisition of Icosavax

News
Article

AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – stock.adobe.com

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – stock.adobe.com

AstraZeneca, a global science-led biopharmaceutical company, has successfully completed its acquisition of US-based clinical-stage biopharmaceutical company, Icosavax, which will become a subsidiary of AstraZeneca. The completion of the acquisition was announced in a Feb. 19, 2024 press release.

Through this acquisition, AstraZeneca will be able to expand its expertise in respiratory syncytial virus (RSV) thanks to Icosavax’s lead investigational vaccine candidate, IVX-A12—a combination protein virus-like particle (VLP) platform vaccine that targets RSV and human metapneumovirus (hMPV). The vaccine, IVX-A12, is ready for Phase III studies and has been granted Fast Track Designation from FDA.

According to Phase II clinical data, IVX-A12 elicits a robust immune response against both RSV and hMPV only one month after vaccination. These data reconfirm previous immunogenicity data seen during the Phase I trial. Currently, there are no treatments or preventative therapies available for hMPV and no combination vaccines available for RSV.

Completion of the acquisition was made through a tender offer for the purchase of all outstanding shares of Icosavax for $15 per share in cash. Additionally, in the event of specified regulator and sales milestones being met, AstraZeneca will pay a non-tradable contingent value of up to $5 per share in cash. In combination, the deal is expected to reach a value of $1.1 billion.

The definitive acquisition agreement between the two companies was announced back in a Dec. 15, 2023 press release, when Iskra Reic, executive vice-president, Vaccines & Immune Therapies, AstraZeneca commented: “With the addition of Icosavax’s Phase III-ready lead asset to our late-stage pipeline, we will have a differentiated, advanced investigational vaccine, and a platform for further development of combination vaccines against respiratory viruses. This aligns with our strategy to deliver a portfolio of therapies to address high unmet needs in infectious diseases, and our ambition to protect the most vulnerable patients who have high risk of severe outcomes.”

Source: AstraZeneca

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Related Content